Segment Results - Schedule of Disaggregation of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 699,727	$ 714,696	$ 1,420,138	$ 1,415,223
Product line revenue reporting threshold			25,000
Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	209,013	212,637	412,538	412,872
Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	244,280	217,843	514,328	433,697
Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	217,784	241,236	436,310	490,476
International Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	28,650	42,980	56,962	78,178
XIAFLEX® | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	74,855	63,500	143,362	120,641
SUPPRELIN® LA | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	23,714	19,963	45,770	40,540
Other Specialty | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	25,524	22,585	49,927	41,612
Total Specialty Products | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	124,093	106,048	239,059	202,793
PERCOCET® | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	28,878	30,833	59,638	62,809
TESTOPEL® | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	11,780	13,844	27,594	29,014
Other Established | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	44,262	61,912	86,247	118,256
Total Established Products | Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	84,920	106,589	173,479	210,079
Vasostrict® | Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	116,026	106,329	255,163	220,054
ADRENALIN® | Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	45,835	36,658	93,157	66,398
Ertapenem for injection | Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	25,547	0	57,766	0
Other Sterile Injectables | Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET	$ 56,872	$ 74,856	$ 108,242	$ 147,245
Sales Revenue, Net | Product Concentration Risk | International Pharmaceuticals
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	4.00%	6.00%	4.00%	6.00%
Sales Revenue, Net | Product Concentration Risk | Colchicine Tablets | Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	7.00%		6.00%